REG - Avacta Group PLC - Notice of Preliminary Results and Presentation

AvactaAnnouncement

Wed 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260513:nRSM0552Ea&default-theme=true

RNS Number : 0552E  Avacta Group PLC  13 May 2026

 

Notice of Preliminary Results and Investor Presentation

 

 

LONDON AND PHILADELPHIA - May 13, 2026 -  Avacta Therapeutics (AIM: AVCT,
"the Company", "Avacta"), a clinical stage biopharmaceutical company
developing pre|CISION(®), a tumor-activated oncology delivery platform,
confirms it will announce its unaudited preliminary results for the year ended
December 31, 2025 ("FY25"), on May 19, 2026.

 

Christina Coughlin, Chief Executive Officer, and Brian Hahn, Chief Financial
Officer, will deliver a live presentation via Investor Meet Company at 14:00
BST on May 19, 2026.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
09:00 BST on May 18, 2026, or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet AVACTA
GROUP PLC via:
https://www.investormeetcompany.com/avacta-group-plc/register-investor
(https://www.investormeetcompany.com/avacta-group-plc/register-investor)

 

Investors who already follow Avacta on the Investor Meet Company platform will
automatically be invited.

 

The Company will also post the results presentation on its website at the
following page: https://avacta.com/investors/investor-resources/
(https://avacta.com/investors/investor-resources/) .

 

 

-Ends-

 

For further information from Avacta, please contact:

 

 Avacta Group plc                                   https://avacta.com/ (https://avacta.com/)

 Christina Coughlin, Chief Executive Officer        via Cohesion Bureau

 Strand Hanson Limited (Nominated Adviser)          www.strandhanson.co.uk (http://www.strandhanson.co.uk)

 James Harris / Chris Raggett / James Dance

 Zeus (Broker)                                      www.zeuscapital.co.uk (http://www.zeuscapital.co.uk)

 James Hornigold / George Duxberry / Dominic King

 Cohesion Bureau                                    avacta@cohesionbureau.com (mailto:avacta@cohesionbureau.com)

 Communications / Media / Investors

 Richard Jarvis

 

About Avacta - https://avacta.com/ (https://avacta.com/)

Avacta Therapeutics is a clinical-stage life sciences company expanding the
reach of highly potent cancer therapies through its proprietary pre|CISION®
platform. pre|CISION® is a payload delivery system based on a tumor-specific
protease (Fibroblast Activation Protein or FAP) that is designed to
concentrate highly potent payloads in the tumor microenvironment while sparing
normal tissues. Avacta's innovative pre|CISION® peptide drug conjugates (PDC)
are a novel entry to the XDC drug class, leveraging the success of antibody
drug conjugates with alternative methods of delivery beyond antibodies.

 

Our pre|CISION® PDCs leverage this tumor-specific release mechanism to
provide unique benefits over traditional antibody drug conjugates, releasing
active payload in the tumor and reducing systemic exposure and toxicity which
enables dosing to be optimized to deliver the best outcomes for patients. The
lead clinical program is faridoxorubicin (AVA6000), a Gen One FAP-enabled
pre|CISION® version of doxorubicin that delivers the payload directly in the
tumor with limited peripheral blood exposure and has demonstrated preliminary
activity in tumor types sensitive to doxorubicin including salivary gland
cancer and soft tissue sarcoma.

 

About AVA6103 (FAP-Exd)

 

AVA6103 is the second clinical candidate and is based on the innovative
pre|CISION(®) sustained release mechanism that provides for prolonged release
of payload directly in the tumor, minimizing systemic exposure.  AVA6103 is
being evaluated in the FOCUS-01 Phase 1 trial (FAP-Exd in Oncologic Cancers
with Unmet needS). Preclinical data suggest this approach has optimized
payload delivery with a high intratumoral concentration and prolonged exposure
of released payload in the tumor, coupled with limited systemic exposure to
the released payload.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORAKBBNOBKDAPD



            Copyright 2019 Regulatory News Service, all rights reserved